

FOR IMMEDIATE RELEASE

August 31, 2016

**PluroGen Therapeutics, LLC Announces Its Participation at the
World Union of Wound Healing Societies (WUWHS) Congress in Florence, Italy, September 25 to 29, 2016**

Norristown, PA - PluroGen Therapeutics, LLC, a biotech company that provides clinically advanced topical products for chronic (non-healing) wounds and burns, today announced that it will participate in the World Union of Wound Healing Societies (WUWHS) Congress in Florence, Italy, September 25 to 29, 2016.

The mission of the WUWHS congress is to promote a greater coalescence and integration of all the Scientific Societies around the world that have the care of skin wounds as their primary focus. Novel technologies, meticulous procedures in wound care, clinical findings and daily practices are discussed throughout. WUWHS 2016 will offer an extensive scientific program including numerous symposia, training sessions, workshops and focus sessions with leading international experts in the field of wound management.

“PluroGen, with our corporate partner Medline Industries, Inc., is very excited to attend this important Congress” said Neal Koller, President and CEO of PluroGen. “Nonhealing wounds are a significant problem worldwide and rates of clinical wound closure remain unacceptably low. As a company that provides innovative products to these patients, we feel strongly about our participation and contribution to the field of wound care. In a recently [published study from 10 centers on 1036 patients](#), an unprecedented 70% of the patients achieved wound closure using PluroGel PSSD Micelle Matrix Product.”

PluroGel is a unique, biocompatible, cell-friendly, surfactant-based biomaterial and is beneficial in all phases of wound healing and for all tissue types. Developed at the world-renowned University of Virginia, PluroGel Micelle Matrix Products give doctors, nurses, patients and consumers advantaged and cost effective new tools for skin, burn and wound care.

PluroGen representatives will be available throughout the conference for one-on-one meetings with health care professionals at **Booth #133**. To set up a meeting during the show, please email europa@plurogen.com.

About PluroGen Therapeutics

PluroGen Therapeutics, LLC, is a burn, wound, and skin care company that develops, manufactures and markets its proprietary line of PluroGel® Micelle Matrix Products. PluroGen’s patent-protected technology is derived from its surfactant-based PluroGel Micelle Matrix (PMM) Biomaterial, providing physicians and patients with new, paradigm-shifting and superior products for burns and chronic wound care. PluroGel products offer Multi-Function advantages and have been routinely used worldwide with documented beneficial and clinically advanced results in patients.

About World Union of Wound Healing Societies (WUWHS)

The theme of the Conference, “One Vision, One Mission” has been the leading principle since the candidature of Italy to host the 5th Congress and it suggests our strong purpose to promote greater aggregation and integration within the World Union of Wound Healing Societies. The most pressing objective is to develop and implement projects to strengthen the central role of the WUWHS, which needs to become more of a worldwide scientific point of reference and a standard for innovation and translational research into the management of skin wounds, together with the improvement of the quality of life of afflicted patients and their families.

Contact Information:

Lori Kavle
+1 (610) 539-3670
lkavle@plurogen.com
www.plurogen.com

Safe Harbor Statement:

The statements in the press release that relate to PluroGen’s (the company) expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company’s actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.